Promethera Biosciences pulls in $11 mln
Promethera Biosciences SA, a Belgian cell therapy and regenerative medicine company targeting liver diseases, has raised $11 million in funding. The investors included Vesalius Biocapital, SRIW, Boehringer Ingelheim Venture Fund, SMS Investments, Mitsubishi UFJ Capital Co. Ltd. and Cell Innovation Partners LP.
28 October 2016•1 min read
